The Coretec Group, Inc., (OTCQB: CRTG), developers of engineered silicon and 3D volumetric displays, has entered into an agreement with Richman Chemical Inc. (RCI) to supply The Coretec Group’s Cyclohexasilane (CHS) to North American customers.
Due to increasing supply chain difficulties and overseas shipping delays due to the COVID19 pandemic, it was important that The Coretec Group work with a US company to supply our North American partners with CHS. On November 15th, The Coretec Group signed a supply agreement with Richman Chemical for the first run of CHS as well as experimental processing. Richman, as The Coretec Group’s domestic supply partner, will accelerate the domestic delivery times of CHS to customers and partners in the US.
“Richman’s expertise in custom synthesis from lab-scale to production is crucial to Coretec’s success. We additionally look forward to a collaborative relationship, working directly with their chemists and engineers on site as appropriate,” said Michelle Tokarz, VP of Partnerships and Innovation, at The Coretec Group.
Christopher Kulp, Chief Commercial Officer of RCI, added, “The Coretec Group’s engineered silicon technology is a game-changer for the energy, display, and printable electronics markets. We are proud to provide a domestic development and scale-up solution that meets the company’s rigorous technical demands. Ultimately, we strive to condense commercialization timelines for our customers, and that is our over-arching priority for CRTG.”
